PF-06751979
目录号: PL13296 纯度: ≥99%
CAS No. :1818339-66-0
商品编号 规格 价格 会员价 是否有货 数量
PL13296-5mg 5mg ¥5563.64 请登录
PL13296-10mg 10mg ¥9272.73 请登录
PL13296-25mg 25mg ¥18545.45 请登录
PL13296-50mg 50mg ¥27200.00 请登录
PL13296-100mg 100mg ¥40800.00 请登录
PL13296-200mg 200mg 询价 询价
PL13296-500mg 500mg 询价 询价
PL13296-10mM*1mLinDMSO 10mM*1mLinDMSO ¥6120.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
PF-06751979
英文名称
PF-06751979
英文别名
N-(2-((4aR,6S,8aR)-2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl)thiazol-4-yl)-5-(difluoromethoxy)picolinamide;1Y0Y126GUG;US9315520, Comparator 1;US9315520, Example 1;US9315520, Example 2;BDBM223395;DB15105;US9315520, 1;2-Pyridinecarboxamide, N-[2-[(4aR,6S,8aR)-2-amino-4,4a,5,6-tetrahydro-6-methylpyrano[3,4-d][1,3]thiazin-8a(8H)-yl]-;PF-06751979
Cas No.
1818339-66-0
分子式
C18H19F2N5O3S2
分子量
455.50
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
PF-06751979 是一种有效的,脑渗透性的 β-淀粉样前体蛋白裂解酶1 (BACE1) 抑制剂,IC50 为 7.3 nM。
生物活性
PF-06751979 is a potent, brain penetrant, β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC 50 of 7.3 nM in BACE1 binding assay.
性状
Solid
IC50 & Target[1][2]
IC50: 7.3 nM (BACE1), 194 nM (BACE2)
体外研究(In Vitro)
PF-06751979 shows improved selectivity over BACE2 (IC50=194 nM) in binding (27-fold) relative to the literature examples and across multiple chemical series in BACE1 program. PF-06751979 also inhibits BACE1 and BACE2 in a fluorescent polarization (FP) assay with IC50s of 26.9 nM and 238 nM, respectively. PF-06751979 has excellent potency at BACE1 in binding or FP assay formats along with cellular activity looking at production of sAPPβ in H4 cells with an IC50 of 5 nM. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
PF-06751979 displays excellent brain penetration, potent in vivo efficacy, and broad selectivity over related aspartyl proteases including BACE2. Acute administration of PF-06751979 yields a robust dose-responsive and time-dependent reduction of cerebral spinal fluid (CSF) Aβx-40 with peak inhibition at 3 h of >77%. To determine if the reduction in brain and CSF Aβ is maintained during sustained exposure to PF-06751979, a 5 day subchronic study is executed, dosing once daily by subcutaneous (SC) administration (10 or 50 mg/kg/day). Brain and CSF samples are collected on day 5, following the last dose. PF-06751979 produces a dose-responsive and time-dependent inhibition of Aβ42 in mouse brain. At the 50 mg/kg/day dose, maximal brain lowering is 63% at 7 to 9 h. Administration of PF-06751979 (10 or 50 mg/kg/day for 5 days) produces a dose-responsive and time-dependent inhibit
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. ONeill BT, et al. Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation. J Med Chem. 2018 May 24;61(10):4476-4504.
溶解度数据
In Vitro: DMSO : 150 mg/mL (329.31 mM; Need ultrasonic)Ethanol : 50 mg/mL (109.77 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2